21/5/2015
Sanofi has announced that the European
Commission has granted marketing authorization in Europe for Toujeo® (insulin
glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin
for the treatment of type 1 and type 2 diabetes mellitus
in adults.
"The
EU marketing authorization for Toujeo represents a significant milestone for
Sanofi, expanding our integrated portfolio of solutions for people with
diabetes in Europe," commented Pierre Chancel, Senior Vice-President,
Global Diabetes, Sanofi. "Toujeo gives people with diabetes and their physicians
a new option to manage their condition, and also reinforces our commitment to
continue improving the quality of diabetes care."